Table 1.
Patient Demographics and Baseline Characteristics for patients with Retinal Vein Occlusion who received a dexamethasone implant
| Variable | BRVO (N=17) |
CRVO (N=23) |
|---|---|---|
| Age in years median (range) | 72 (54-89) | 74 (54-90) |
| Gender/Females n (%) | 5 (29.4%) | 11 (47.8%) |
| Median disease duration (months) | 40 | 45 |
| Retinal nonperfusion based upon wide angle FA n (%) | ||
| Mild | 9 (52.9) | 12 (52.2) |
| Moderate | 4 (23.5) | 4 (17.4) |
| Severe | 2 (l1.8) | 4 (17.4) |
| No gradable FA | 2 (11.8) | 3 (13.0) |
| Prior anti-VEGF injections* | ||
| Mean (range) | 13.9 (1-36) | 18.9 (2-41) |
| Response to anti-VEGF injections | ||
| Gooda | 4 | 11 |
| Poorb | 8 | 9 |
| Indeterminatec | 5 | 3 |
| Prior Intraocular Steroids n (%) | 5 (29.4%) | 1 (4.3%) |
| Grid laser (%) | 5 (29.4) | 8 (34.8) |
| Scatter Laser photocoagulation (%) | 4 (23.5) | 13 (56.5) |
| Baseline BCVA (letter score) | ||
| Median (range) | 60 (29-71) | 54 (19-76) |
| Baseline CST (μm) | ||
| Median (range) | 453 (225-792) | 539 (251-941) |
| Baseline intraretinal fluid | ||
| Mild | 4 | 1 |
| Moderate | 4 | 9 |
| Severe | 9 | 13 |
*
Based upon verified observed data and electronic patient records for 14 BRVO and 21 CRVO patients
a
Good response = elimination of all or most intraretinal fluid during periods of monthly or less frequent injections
b
Poor response = substantial recurrent/residual intraretinal fluid even during periods of monthly injections
c
Indeterminate = unable to determine from available data
Abbreviations: BRVO = branch retinal vein occlusion, CRVO = central retinal vein occlusion, BCVA = best-corrected visual acuity, CST = central subfield thickness, VEGF = vascular endothelial growth factor, μm = microns, FA = fluorescein angiogram